The Lubrizol Corporation’s LifeSciences business, a leading supplier of services and advanced materials for the pharmaceutical and medical device industry, announces it will showcase its expanded range of solutions for the pharmaceutical industry at the 2016 American Association of Pharmaceutical Scientists (AAPS) annual meeting and exposition November 14 -17 at the Colorado Convention Center in Denver, Colorado (Booth #1127).
Lubrizol LifeSciences will highlight the drug product development capabilities of Particle Sciences – a leading contract drug development and manufacturing organization with a comprehensive suite of services for the formulation, analysis and production of complex drug delivery solutions.
Lubrizol LifeSciences continues to expand its capabilities at Particle Sciences, providing full service cGMP drug product development and manufacturing across a variety of sterile and non-sterile complex dosage forms such as micro/nano-particulates, emulsions and drug-eluting devices. “With the new investment in over 2,700 ft2 of commercial cleanroom space, we continue to demonstrate our commitment to be the leading CDMO for complex drug products. Our organization has a depth of knowledge and resources found nowhere else,” stated Mark Mitchnick M.D., CEO, Particle Sciences Inc., chief medical officer, Lubrizol LifeSciences.
Lubrizol LifeSciences’ newest product, Transform(TM), is the only hydrate-able topical film that offers wide API compatibility, value and convenience all in one. Transform films make loading APIs for drug delivery fast and easy. This can eliminate additional raw materials and processing steps of lamination and multiple components. Improved patient comfort is another benefit as Transform is a cool, comfortable, transparent film designed for optimal aesthetics and therapeutic benefit.
The Lubrizol Corporation